All NIAID articles
-
News‘Unbreakable’ Lassa vaccine shows promising results
A live-attenuated vaccine candidate against Lassa virus completely protected guinea pigs exposed to an otherwise lethal dose of the virus, researchers have reported.
-
News$12 million grant to research how vaccines induce lasting immunity
Researchers have received a $12 million grant to study how vaccines trigger long-lasting immune responses. The work may inform the design of new, more protective vaccines for respiratory viruses, including SARS-CoV-2 and influenza.
-
NewsResearchers awarded $3 million grant to explore gut health
A $3 million grant has been awarded to investigate the energy generating processes of gut Bacteroides and how they impact our well-being.
-
NewsNIH releases mpox research agenda
National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has released an update on its priorities for mpox research, which focus on four key objectives.
-
NewsScientists awarded $90m to prep for future pandemics from understudied viruses
Scientists are laying the groundwork to rapidly respond to potential future pandemics caused by viruses from five understudied families, developing strategies and tools to produce vaccines and antibody-based therapies.
-
NewsNew lab test to detect persistent HIV strains in Africa may aid search for cure
A multinational team has developed a test that will help measure the persistence of HIV in people affected by viral strains found predominantly in Africa—a vital tool in the search for an HIV cure that will benefit patients around the world.
-
NewsBacteria discovery leads to novel probiotic for eczema
Research has led to the availability of a new over-the-counter topical eczema probiotic, based on the discovery that bacteria present on healthy skin called Roseomonas mucosa can safely relieve eczema symptoms in adults and children.
-
NewsInfectious H5N1 influenza virus in raw milk rapidly declines with heat treatment
The amount of infectious H5N1 influenza viruses in raw milk rapidly declines with heat treatment, but small amounts of infectious virus remain in raw milk samples with high virus levels when treated at 72 degrees Celsius for 15 seconds.
-
NewsNIAID releases H5N1 influenza research agenda
The National Institute of Allergy and Infectious Diseases (NIAID) has released its plan for advancing H5N1 influenza basic research and translating those findings into strategies and interventions that can benefit people.
-
NewsBody lice may be bigger plague spreaders than previously thought
A new laboratory study suggests that human body lice are more efficient at transmitting Yersinia pestis, the bacterium that causes plague, than previously thought, supporting the possibility that they may have contributed to past pandemics.
-
NewsExperimental NIH malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial.
-
News Antimicrobial-resistant hospital infections remain at least 12% above pre-pandemic levels, major US study finds
Despite progress in combating antimicrobial resistance (AMR) in the USA since its peak during the COVID-19 pandemic, hospital-acquired AMR infections remain well above pre-pandemic levels, according to a major new study examining AMR before, during, and after the COVID-19 pandemic in 120 US hospitals. Source: NIAID Colorized scanning ...
-
NewsA combination of approved drugs enhances the delivery of anti-bacterial medications to treat tuberculosis
Scientists repurposed approved drugs that they originally tested to normalize blood vessels surrounding tumors to improve drug delivery to cancer cells.
-
NewsClinical trial of HIV vaccine begins in United States and South Africa
A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people. Source: NIAID Transmission electron micrograph ...
-
NewsClinical trial of mRNA universal influenza vaccine candidate begins
A clinical trial of an experimental universal influenza vaccine, H1ssF-3928 mRNA-LNP, has begun enrolling volunteers to test for safety and its ability to induce an immune response.
-
NewsMonoclonal antibody programme targets mucormycosis
Vitalex Biosciences has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health for VX-01, a monoclonal antibody (mAB) programme targeting the debilitating indication of the fungal disease, mucormycosis.
-
NewsPhase 2 trial of Ebola vaccines yields promising results
An international team of scientists has published the results of a large-scale randomized clinical trial in West Africa which confirms the safety of three vaccine regimens for Ebola and suggests an immune response is induced and maintained for up to 12 months.